



DERMAGNOSTIX



Explore more: [www.dermagnostix.com](http://www.dermagnostix.com)



Contact us:  
[info@dermagnostix.com](mailto:info@dermagnostix.com)

moving diagnostic frontiers  
in dermatology

## Skin diseases are on the rise

One third of the population suffers from at least one skin condition. Incidences of psoriasis, atopic dermatitis and melanoma have doubled during the past decades.

Skin diseases impair patients' quality of life more drastically than cancer and diabetes.

As modern therapies of common diseases such as psoriasis and eczema are fundamentally different, misdiagnosed patients may not only receive ineffective but even harmful therapies.



## PsorX: The first molecular test for psoriasis and eczema – a breakthrough for inflammatory skin diseases


“All member states of the WHO recognized the burden of psoriasis and [...] that too many people in the world suffer needlessly from psoriasis due to incorrect or delayed diagnosis.” World Health Assembly 67.9, May 2014

## Modern therapies require modern diagnostics

The availability of innovative therapies like biologicals and small-molecule inhibitors has created an unprecedented potential for precision medicine.

At Dermagnostix, groundbreaking translational biomarker research meets cutting-edge microfluidics technology. With our unique diagnostic LabDisk tests we

address unmet clinical needs in dermatology on a fully automated portable laboratory to advance clinical practice and improve patients' lives.



Psoriasis and atopic eczema or other forms of eczema are amongst the most common inflammatory diseases. However, up to 50 % of patients with psoriasis and eczema are misdiagnosed due to substantial overlap between both entities. Therefore, modern biologicals and small-molecule inhibitors tailored for either psoriasis or eczema fall short of their therapeutic potential.

Over a decade of research, we have succeeded in developing a test which – based on the gene expression of NOS2 and CCL27 – detects the molecular signature of psoriasis versus eczema with very high sensitivity and specificity and thus supports differential diagnosis of these diseases. Easy and reliable at the point-of-need.

